Trials & Tribulations MRI-guided radiotherapy for prostate cancer: Lessons from the MIRAGE trial February 03, 2023Vol.49 No.05By Amar U. Kishan
Clinical Roundup KEYNOTE-991 trial evaluating Keytruda + Xtandi + androgen deprivation therapy in hormone-sensitive prostate cancer is stopped for futility February 03, 2023Vol.49 No.05
Guest Editorial Ending cancer as we know it—for everyone—begins with the numbers January 13, 2023Vol.49 No.02By William L. Dahut
Clinical Roundup Phase III trial of TAVT-45 in metastatic prostate cancer yields positive top-line results January 06, 2023Vol.49 No.01
In Brief Prostate Cancer Foundation awards $30M in new funding for innovative research December 09, 2022Vol.48 No.44
Drugs & Targets Lynparza receives positive CHMP opinion for metastatic, castration-resistant prostate cancer November 18, 2022Vol.48 No.42
Clinical Roundup UCSD and VA San Diego study shows genetic score predicts risk of prostate cancer November 04, 2022Vol.48 No.40
Clinical Roundup New analysis finds sequencing androgen-deprivation therapy with radiation therapy improves outcomes in localized prostate cancer October 28, 2022Vol.48 No.39
Clinical Roundup Metastasis-directed radiation therapy plus hormone therapy improves PFS for men with advanced prostate cancer October 28, 2022Vol.48 No.39
